HUMAN PARAOXONASE 1 – PARACLINICAL MARKER WITH CLINICAL APPLICATION IN THE PREVENTION OF ACUTE CARDIOVASCULAR EVENTS
 |
Read full article |
| Article Title: | HUMAN PARAOXONASE 1 – PARACLINICAL MARKER WITH CLINICAL APPLICATION IN THE PREVENTION OF ACUTE CARDIOVASCULAR EVENTS |
| Authors: | Camelia Ciacli*1, Calin Popa2, Maria Puschita1 |
| Affiliation: | 1 Faculty of General Medicine, Pharmacy and Dental Medicine from „Vasile Goldis” Western University of Arad (Romania); 2 Institute of Cardiovascular Medicine Timisoara (Romania) |
| Abstract: | Paraoxonases are a group of enzymes consisting of three sub-types that were originally discovered for their involvement in the hydrolysis of organophosphatases. Objectives of our study included determination of human paraoxonase 1 (PON1) values at the patients with the highest risk of cardiovascular disease and correlation of the results with the markers of atherosclerosis. We selected a total of 120 hypertensive without chronic treatment; group II (H2) consisting of 30 subjects diagnosed with hypertension, impaired glucose tolerance, obesity (metabolic syndrome); group III (H3) also included 30 patients with hypertension and type II diabetes; group IV (H4) included 30 patients hypertensive with type II diabetes and renal disorders. The control group included 25 clinically healthy subjects. For estimation of the immediately atherogenic risk, atherogenic index of plasma (AIP) is more sensitive to changes in lipid fractions values. Determining the PON1 can, however, estimate the long-term risk of developing cardiovascular diseases. PON1 value is more accurate than AIP for estimating cardiovascular risk, even if PON1 values may be influenced by many factor it may indicate accurately the risk of cardiovascular disease. |
| Keywords: | paraoxonases – atherosclerosis – hypertension – diabetes – obesity – acute cardiovascular events |
| References: | Alwan A. et al.: Monitoring and surveillance of chronic noncommunicable diseases:progress and capacity in high burden countries. Lancet, 2010; 376: 1861–1868. Aviram M., Rosenblat M. – Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell during atherosclerosis development. Free Radic Biol Med 37, 2004 pp.1304–1316. Bakhit M., Al-Najai M., Vigilla M., Al-Boudari O., Muiya P., Meyer B., ALMohanna F., Alshahid A., Dzimiri N. – The PON1 is a susceptibility gene for hypertension. The FASEB Journal 24, 2010, pp.524-525 Blatter M., Moren X., Richard W. – Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. Journal of Lipid Research, Volume 47, 2006, pp.515-520. Dobiasova M., Atherogenic index of plasma [log(triglyceride/HDL-CColesterol)]: Theoretical and practical implications”, Cli. Chem., 2004; pp:1113-1115. Dobiášová M., Frohlich J., Sedová M., Cheung M.C. and Brown G. – Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography, Journal of Lipid Research Volume 52, 2011; 566-751. Dorobantu M, Darabont R, Badila E, Ghiorghe S. – Prevalence, Awareness,Treatment, and Control of Hypertension in Romania: Results of the SEPHAR Study, Int J Hypertens. 2010 Feb 1; 2010:970694 Flekač M., Skrha J., Zídková K., Lacinová Z., Hilgertová J. – Paraoxonase 1 Gene Polymorphisms and Enzyme Activities in Diabetes. Physiol. Res. 57, 2008, pp. 717-726. Gugliucci A., Kotani K., Kimura S. – Paraoxonase 1 in Chronic Kidney Failure. Journal of Lipids Volume 2012, Article ID 726048, 10 pages. Young M H: Atherosclerotic Cardiovascular Disease Beginning in Childhood. The Korean Society of Cardiology, Korean Circ J 2010;40:1-9. Mendonca I. et al – Polimorfismos do Gene da Paraoxonase Humana e Risco de Doença Coronária. Rev Port Cardiol 2008; 27 (12): 1539-1555. Popa C., Popescu C., Pilat L, Puschita M. – Human paraoxonase 1 (PON1) and its association with cardiovascular disease risk on a group study of young hypertensive patients, Studia Universitatis “Vasile Goldiş”, Seria Ştiinţele Vieţii, Vol. 23, issue 4, 2013, pp. 501-505. World Health Organization The global burden of disease: 2004 update. Geneva, 2008. |
| *Correspondence: | Ciacli Camelia M.D, PhD „Vasile Goldis” Western University of Arad, Tel: +40744635081, e-mail: cciacli@yahoo.com |
About The Author
